COMMUNIQUÉS West-GlobeNewswire

Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer
05/01/2026
Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD [...]
Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
05/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics , a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today [...]
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
05/01/2026
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a [...]
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
05/01/2026
TARA-002 selected for FDA manufacturing development and readiness pilot program NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative [...]
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
05/01/2026
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In [...]
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
05/01/2026
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) [...]
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
05/01/2026
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune [...]
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
05/01/2026
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
HOOPP hits 500,000-member milestone, strengthening retirement security for Ontario’s healthcare community
05/01/2026
Half a million futures. One pension promise. TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan has surpassed the 500,000-membership mark, an important milestone that reflects HOOPP’s [...]
Compass Therapeutics Announces Key Leadership Appointments
05/01/2026
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple [...]
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
05/01/2026
Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. ( [...]
BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
05/01/2026
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, [...]
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
05/01/2026
Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting [...]
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
05/01/2026
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned [...]
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
05/01/2026
UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. ( OTC: PRPH ) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company’s underlying asset [...]
TME Pharma provides update on its activities
05/01/2026
TME Pharma provides update on its activities Berlin, Germany , January 5, 2025, 08.00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel [...]
TME PHARMA FAIT LE POINT SUR SES ACTIVITÉS
05/01/2026
TME PHARMA FAIT LE POINT SUR SES ACTIVITÉS Berlin, Allemagne, 5 janvier 2025, 8 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie au stade clinique spécialisée dans le [...]
Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
05/01/2026
Press Release Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing Company’s position strengthened, enabling flexibility in strategic discussions All [...]
Nicox annonce le remboursement intégral de sa dette avec Kreos Capital et étend son horizon de trésorerie au-delà de 2027 grâce à un nouveau financement complémentaire
05/01/2026
Communiqué de presse Nicox annonce le remboursement intégral de sa dette avec Kreos Capital et étend son horizon de trésorerie au-delà de 2027 grâce à un nouveau financement complémentaire La position de la Société sort [...]

Pages